Gangliosides
are intimately involved in a plenum of (neuro)inflammatory
processes, yet progress in establishing structure–function
interplay is frequently hindered by the availability of well-defined
glycostructures. Motivated
by the ubiquity of the ganglioside GM3 in chemical neurology,
and in particular by its conspicuous presence in myelin, the GM3 epitope was examined with a view to preclinical validation
as a tracer. The suitability of this scaffold for the noninvasive
imaging of oligodendrocyte differentiation in Multiple sclerosis is
disclosed. The stereocontrolled synthesis of a site-selectively fluorinated
analogue (F–GM3) is also disclosed to enable a comparative
analysis in oligodendrocyte (OL) differentiation. Whereas the native
epitope caused a decrease in the viability in a dose-dependent manner,
the addition of distinct F–GM3 concentrations over
48 h had no impact on the OL viability. This is likely a consequence
of the enhanced hydrolytic stability imparted by the fluorination
and highlights the potential of fluorinated glycostructures in the
field of molecular imaging. Given the predominant expression of GM3 in oligodendrocytes and the capacity of GM3 to
interact with myelin-associated proteins, this preclinical evaluation
has revealed F–GM3 to be an intriguing candidate
for neurological imaging.